SB 264 makes targeted changes to New Hampshire’s therapeutic cannabis program. It updates the definition of “provider” to expressly include physician assistants who are licensed in New Hampshire, have the required DEA registration to prescribe controlled substances, and, where applicable, act consistently with their collaboration agreement. The bill also clarifies how concerns about provider conduct are handled and expands existing provider restrictions to cover comparable relationships with cannabis businesses outside New Hampshire.
More specifically, the bill directs that concerns about provider conduct be referred to the appropriate New Hampshire licensing board or, when relevant, the corresponding regulatory entity in Maine, Massachusetts, or Vermont. It also states that if a provider is disciplined in connection with therapeutic cannabis activity, the department may prohibit that provider from participating in New Hampshire’s program. In addition, the bill extends the program’s anti-kickback, anti-steering, examination-location, and financial-interest prohibitions to analogous interactions with out-of-state cannabis dispensaries and other cannabis entities.
Impact
The bill amends RSA 126-X, the therapeutic cannabis statute, by refining who may serve as a certifying provider and by broadening the enforcement reach of existing provider-conduct rules. It affects physician assistants, certifying providers, alternative treatment centers, cannabis dispensaries, and other cannabis businesses, including those located outside New Hampshire. The practical effect is to align the therapeutic cannabis program more closely with professional licensing rules and to give regulators clearer authority to address provider misconduct tied to cannabis certification.
Sentiment
The available context suggests the bill was introduced as a department request and is largely administrative and clarifying in nature rather than controversial. The language indicates an effort to modernize the program, reduce ambiguity, and ensure consistent oversight of providers. No committee transcript or vote record is provided, so there is no documented opposition or support beyond the bill’s sponsorship and request status.
Contention
The main points of potential contention are the expansion of regulatory oversight beyond New Hampshire and the extension of provider restrictions to out-of-state cannabis entities. Providers and cannabis businesses could view these provisions as increasing compliance burdens or limiting business relationships, while regulators and public-health advocates may see them as necessary safeguards against conflicts of interest and misconduct. Another possible issue is the requirement that physician assistants comply with collaboration-agreement limits when prescribing in connection with therapeutic cannabis certifications, which may be seen as either a necessary professional safeguard or an added administrative constraint.